How should I manage dyspepsia and throat discomfort that began after starting regular omalizumab injections, given that I have been on a proton‑pump inhibitor for the past 3–4 months?

Management of Dyspepsia and Throat Discomfort After Starting Omalizumab

Since you have been on a PPI for 3-4 months without adequate symptom control, you should undergo upper endoscopy to investigate for organic pathology, and if negative, consider PPI discontinuation or dose optimization rather than continuing ineffective therapy indefinitely. 1

Diagnostic Approach

Your situation requires objective evaluation because:

• PPI therapy beyond 8 weeks without response suggests either:

  • No acid-related pathology exists
  • An alternative diagnosis is present
  • The symptoms are not GERD-related

• According to 2022 AGA guidelines, if PPI therapy is continued in a patient with unproven GERD, appropriateness should be evaluated within 12 months of initiation 1

Recommended Testing Sequence:

1. Upper endoscopy first to evaluate for:

   • Erosive esophagitis (Los Angeles classification)
   • Barrett's esophagus
   • Peptic ulcer disease
   • Other mucosal abnormalities
   • Eosinophilic esophagitis (obtain biopsies)

2. If endoscopy is negative, perform prolonged wireless pH monitoring OFF PPI therapy (96-hour preferred if available) to confirm or rule out GERD 1, 2

Critical Consideration: Omalizumab Connection

The FDA label for omalizumab does not list dyspepsia or throat discomfort as common adverse effects 2. However, the temporal relationship you describe warrants consideration of:

• Alternative diagnoses (eosinophilic esophagitis, given omalizumab is used for allergic conditions)
• Coincidental GERD unrelated to omalizumab
• Functional dyspepsia triggered by medication initiation

Management Strategy Based on Your Current Situation

Since PPIs Have Failed After 3-4 Months:

Do NOT increase PPI dose to twice daily - the 2022 AGA guidelines suggest against increasing PPI dose in patients who have received 8 weeks of twice-daily PPI without response 3

Consider PPI De-prescribing:

You may be experiencing rebound acid hypersecretion (RAHS), which can occur after prolonged PPI use and paradoxically worsen symptoms 3. The approach:

• Either taper or abruptly discontinue - both strategies are reasonable 3
• Expect temporary worsening of symptoms for up to 2 months (this is RAHS, not necessarily true GERD)
• Use on-demand H2-receptor antagonists or antacids for breakthrough symptoms during this period 3
• Severe persistent symptoms lasting >2 months after discontinuation suggest a true indication for PPI therapy 3

If You Continue PPIs:

Use adjunctive therapy personalized to your symptoms 1:

• Alginate antacids for breakthrough symptoms
• Nighttime H2-receptor antagonists if nocturnal symptoms predominate
• Avoid empiric prokinetics without proven gastroparesis

Common Pitfalls to Avoid

1. Do not continue ineffective PPI therapy indefinitely - this is inappropriate prescribing 3, 4

2. Do not assume all upper GI symptoms are acid-related - up to 50% of suspected GERD patients do not benefit from acid suppression 1

3. Do not confuse RAHS symptoms with treatment failure - temporary symptom worsening after PPI discontinuation is expected and does not mandate immediate PPI resumption 3

4. Do not undergo anti-reflux procedures without objective GERD confirmation 5

Evidence Quality Note

The recommendations for PPI de-prescribing and diagnostic evaluation come from high-quality 2022 AGA guidelines published in Gastroenterology and Clinical Gastroenterology and Hepatology 3, 1. Research evidence supports that PPI monotherapy is effective for true acid-related dyspepsia 6, 7, 8, but your lack of response after 3-4 months strongly suggests this is not your diagnosis.

The key decision point: proceed with endoscopy now to guide further management rather than continuing empiric therapy that has already failed.